@article {7747,
	title = {Risk factors for, and reversibility of, peripheral neuropathy associated with bortezomib-melphalan-prednisone in newly diagnosed patients with multiple myeloma: Subanalysis of the phase 3 VISTA study},
	journal = {European Journal of Haematology},
	volume = {86},
	year = {2011},
	note = {Cited By :50Export Date: 21 February 2017},
	month = {2011},
	pages = {23 - 31},
	abstract = {Objectives: This subanalysis of the phase 3 VISTA trial aimed to assess the frequency, characteristics and reversibility of, and prognostic factors for, bortezomib-associated peripheral neuropathy (PN) in newly diagnosed patients with multiple myeloma ineligible for high-dose therapy who received bortezomib plus melphalan-prednisone.Methods: Patients received nine 6-wk cycles of VMP (bortezomib 1.3 mg/m2, days 1, 4, 8, 11, 22, 25, 29, 32, cycles 1-4, and days 1, 8, 22, 29, cycles 5-9; melphalan 9 mg/m2, days 1-4, cycles 1-9; and prednisone 60 mg/m2, days 1-4, cycles 1-9).Results: Overall, 47\% of patients receiving VMP developed PN, including 19\% grade 2 and 13\% grade >=3 (\&lt;1\% grade 4). The PN incidence was dose-related and reached a plateau at a cumulative bortezomib dose of approximately 45 mg/m2. Median time to PN onset was 2.3 months. Bortezomib-associated PN was reversible; 79\% of events improved by at least one NCI CTCAE grade within a median of 1.9 months and 60\% completely resolved within a median of 5.7 months, with reversibility similar in responding and non-responding patients. By multivariate analysis, baseline neuropathy was the only consistent risk factor for any PN [hazard ratio (HR) 1.785, P = 0.0065], grade >=2 PN (HR 2.205, P = 0.0032), and grade >=3 PN (HR 2.438, P = 0.023); age, pre-existing diabetes, International Staging System stage, obesity, and creatinine clearance did not affect the overall rate of PN.Conclusions: Rates of bortezomib-induced PN in the frontline setting were similar to those in relapsed patients and resolved in most cases. (Clinicaltrials.gov identifier: NCT00111319). {\textcopyright} 2010 John Wiley \&amp; Sons A/S.},
	keywords = {bortezomib, multiple myeloma, peripheral neuropathy, Phase 3, Subanalysis, VISTA},
	url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-78650110658\&doi=10.1111\%2fj.1600-0609.2010.01533.x\&partnerID=40\&md5=09bbfbbf2f1d5155e0de1dcfefd39471},
	author = {Dimopoulos, M.A. and Mateos, M.-V. and Richardson, P.G. and Schlag, R. and Khuageva, N.K. and Shpilberg, O. and Kropff, M. and Spicka, I. and Palumbo, A. and Wu, K.L. and Esseltine, D.-L. and Liu, K. and Deraedt, W. and Cakana, A. and van de Velde, H. and San Miguel, J.F.}
}
